Ticker

PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person…

PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026.

ImmuCell Corporation (NASDAQ: ICCC - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $6.11 and traded as high as $6.45. ImmuCell shares last traded at $6.44, with a volume of 2,936 shares trading hands. Analyst Ratings Changes Separately, Weiss Ratings raised shares

PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board…

ImmuCell (NASDAQ: ICCC) executives used the company's fourth-quarter and full-year 2025 earnings call to highlight a year of operational change, improved margins, and a strategic pivot toward expanding its First Defense calf scours prevention franchise while stepping away from investment in its Re-Tain subclinical mastitis program. 2025 results: sales growth and margin expansion Chief Financial Officer